Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Immune checkpoint inhibitors (ICIs) offer unique benefits for advanced Mismatch Repair-deficient/Microsatellite instable (dMMR/MSI) colorectal cancer.
• However, ICIs have shown limited efficacy in Mismatch Repair-proficient/Microsatellite stable (pMMR/MSS) colorectal cancer.
• A significant proportion of dMMR/MSI cancer patients progress despite PD-1 blockade, necessitating predictive biomarkers.

Purpose of the Study:

• To review current advancements in immunotherapy for dMMR/MSI and pMMR/MSS colorectal cancers.
• To explore the distinct immune profiles and escape mechanisms in pMMR/MSS tumors.
• To discuss the need for biomarkers to guide patient selection for combination immunotherapies.

Main Methods:

• Literature review of recent studies on immunotherapy in colorectal cancer.
• Analysis of immune profiles in dMMR/MSI versus pMMR/MSS colorectal tumors.
• Discussion of potential biomarkers for predicting immunotherapy response.

Main Results:

• ICIs demonstrate differential efficacy based on MMR/MSI status in colorectal cancer.
• pMMR/MSS colorectal cancers exhibit unique immune evasion strategies.
• Biomarkers like tumor mutational burden and Immunoscore® may guide treatment selection.

Conclusions:

• Individualized immunotherapeutic strategies are needed for pMMR/MSS colorectal cancer.
• Further research is required to identify optimal biomarkers for ICI therapy selection.
• Biomarker-guided approaches hold promise for improving outcomes in colorectal cancer immunotherapy.